Capricor Therapeutics, Inc. (CAPR) Stock: Here’s What’s Happening

0

Capricor Therapeutics, Inc. (CAPR) is headed down in the market in today’s trading session. The stock, one that is focused on the biotech sector, is presently priced at $2.20 after falling -12.35% so far today. As it relates to biotechnology stocks, there are a number of aspects that have the potential to lead to declines in the market. News is one of the most common reasons for movement. Here are the most recent stories relating to CAPR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-07-19 05:15PM Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates
04:00PM Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
Nov-01-19 09:00AM Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
Oct-27-19 09:16AM How Capricor Therapeutics, Inc. (NASDAQ:CAPR) Can Impact Your Portfolio Volatility
Oct-21-19 09:25AM Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Nonetheless, any time investors are making a decision to invest, prospective investors should focus on much more than just news, especially in the highly speculative biotechnology sector. Here’s what’s happing when it comes to Capricor Therapeutics, Inc..

Trends That We’ve Seen From CAPR

While a single session decline, like the fall that we’re seeing from Capricor Therapeutics, Inc. may make some investors fearful, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always a good idea to look into trends beyond a single session. In the case of CAPR, below are the movements that we have seen:

  • Past Seven Days – Over the past 5 trading sessions, CAPR has generated a change in price that amounts to -13.73%.
  • Monthly – The monthly performance from Capricor Therapeutics, Inc. comes to -11.29%.
  • Quarterly – In the past 3 months, the stock has generated a return that comes to -27.15%
  • Past 6 Months – Over the past 6 months, investors have seen a change that works out to -47.51% from the stock.
  • YTD – Since the close of last year CAPR has resulted in a ROI of -46.34%.
  • Annually – Finally, throughout the last year, investors have seen a change in the amount of -78.22% from CAPR. In this period, the stock has sold at a high of -79.44% and a low of -4.35%.

Ratios Of Note

Digging into various key ratios having to do with a stock can provide traders an understanding of just how dangerous and/or rewarding a an investment option may be. Here are a few of the key ratios to look at when digging into CAPR.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is going to fall. In general, biotech stocks tend to carry a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, in relation to Capricor Therapeutics, Inc., the stock’s short ratio amounts to 0.74.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure whether or not a company can pay for its debts when they mature using quick assets or current assets. Because many biotech several companies are reliant on continued support from investors, these ratios can look bad. Nonetheless, quite a few better companies in the biotechnology space come with good quick and current ratios. In terms of CAPR, the quick and current ratios total up to 4.20 and 4.20 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets owned by the company. In this case, that ratio works out to 0.68.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology industry, this is a very important ratio to look into. In this case, the cash to share value ratio comes to 1.38.

What Analysts Think About Capricor Therapeutics, Inc.

While it’s not a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their thoughts to validate your own thoughts when it comes to making investment decisions in the biotechnology space. Below are the most recent moves that we’ve seen from analysts as it relates to CAPR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-26-18 Downgrade Maxim Group Buy → Hold
Jan-26-18 Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17 Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17 Resumed Rodman & Renshaw Buy $14
Jul-06-16 Resumed H.C. Wainwright Buy $13

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CAPR, here’s what we’re seeing:

Institutions own 2.40% of the company. Institutional interest has moved by 3.02% over the past three months. When it comes to insiders, those who are close to the company currently own 32.93% percent of CAPR shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 4.27M shares of Capricor Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CAPR has a float of 2.63M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CAPR, the short percent of the float is 4.72%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.42. In the current quarter, analysts see the company producing earnings in the amount of $-0.79. Over the last 5 years, CAPR has generated revenue in the amount of $27.10% with earnings coming in at 9.40%. On a quarter over quarter basis, earnings have seen movement of 58.30% and revenue has seen movement of 0.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was made by a human and human beings actually play a crucial role in my ability to learn. Sure, I can look through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here